Fundraising boosts Implant Sciences' breast brachytherapy
This article was originally published in Clinica
Executive Summary
Implant Sciences says it will use some of the $2m it has just raised through a convertible preferred stock placement to develop its brachytherapy technology for treating breast cancer. The cash, provided by existing investor Laurus Funds, will also be used to commercialise the Wakefield, Massachusetts firm's hand-held system for detecting explosives.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.